GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc.
(Nasdaq: NVAX), a biotechnology company dedicated to developing and
commercializing next-generation vaccines for serious infectious
diseases, today announced that it will participate in Cowen's
42nd Annual Healthcare Conference. Novavax' recombinant
nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373,
will be a topic of discussion.
|
Conference
Details:
|
|
|
|
Fireside
Chat
|
|
|
Date:
|
Tuesday, March 8,
2022
|
|
Time:
|
9:50 – 10:20 a.m.
Eastern Standard Time (EST)
|
|
Cowen
Moderator:
|
Georgi Yordanov,
Ph.D.
|
|
Novavax
participants:
|
Filip Dubovsky, M.D.,
Executive Vice President, Chief Medical Officer
and John J. Trizzino, Executive Vice President, Chief
Commercial
Officer and Chief Business Officer
|
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Tuesday, March 8,
2022
|
|
|
|
|
|
|
|
|
|
|
A replay of the recorded fireside session will be available
through the events page of the Company's website at ir.novavax.com
for 90 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that
promotes improved health globally through the discovery,
development and commercialization of innovative vaccines to prevent
serious infectious diseases. The company's proprietary recombinant
technology platform harnesses the power and speed of genetic
engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. NVX-CoV2373, the
company's COVID-19 vaccine, has received conditional authorization
from multiple regulatory authorities globally, including the
European Commission and the World Health Organization. The vaccine
is also under review by multiple regulatory agencies worldwide. In
addition to its COVID-19 vaccine, Novavax is also currently
evaluating a COVID-seasonal influenza combination vaccine in a
Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu,
its quadrivalent influenza investigational vaccine candidate. These
vaccine candidates incorporate Novavax' proprietary saponin-based
Matrix-M™ adjuvant to enhance the immune response and stimulate
high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect
with us on Twitter, LinkedIn, Instagram and Facebook.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey |
202-709-7521
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-cowens-42nd-annual-health-care-conference-301494394.html
SOURCE Novavax, Inc.